Bioventix PLC (LON:BVXP - Get Free Report) announced a dividend on Monday, October 28th, Upcoming.Co.Uk reports. Stockholders of record on Thursday, November 7th will be given a dividend of GBX 87 ($1.13) per share by the biotechnology company on Thursday, November 21st. This represents a dividend yield of 2.4%. The ex-dividend date is Thursday, November 7th. This is a boost from Bioventix's previous dividend of $68.00. The official announcement can be seen at this link.
Bioventix Stock Performance
BVXP traded down GBX 345 ($4.47) during trading on Monday, reaching GBX 3,280 ($42.54). The company had a trading volume of 23,562 shares, compared to its average volume of 5,317. Bioventix has a 12-month low of GBX 3,240 ($42.02) and a 12-month high of GBX 5,100 ($66.14). The company has a market cap of £171.22 million, a price-to-earnings ratio of 2,011.04 and a beta of 0.35. The firm's 50-day simple moving average is GBX 3,964.07 and its 200 day simple moving average is GBX 4,209.03.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Recommended Stories
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
